Literature DB >> 11121061

Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen.

M Noursadeghi1, M C Bickerstaff, J R Gallimore, J Herbert, J Cohen, M B Pepys.   

Abstract

Serum amyloid P component (SAP) binds to Streptococcus pyogenes, and we show here that it also binds to Neisseria meningitidis, including a lipopolysaccharide (LPS)-negative mutant, and to rough variants of Escherichia coli. Surprisingly, this binding had a powerful antiopsonic effect both in vitro and in vivo, reducing phagocytosis and killing of bacteria. Furthermore, SAP knockout mice survived lethal infection with S. pyogenes and rough E. coli J5, organisms to which SAP binds. The susceptibility of SAP(-/-) mice was fully restored by injection of isolated human SAP. However, SAP(-/-) mice were more susceptible than wild-type animals to lethal infection with E. coli O111:B4, a smooth strain to which SAP does not bind, suggesting that SAP also has some host defense function. Although SAP binds to LPS in vitro, SAP(-/-) mice were only marginally more susceptible to lethal LPS challenge, and injection of large amounts of human SAP into wild-type mice did not affect sensitivity to LPS, indicating that SAP is not a significant modulator of LPS toxicity in vivo. In contrast, the binding of SAP to pathogenic bacteria enabled them to evade neutrophil phagocytosis and display enhanced virulence. Abrogation of this molecular camouflage is thus potentially a novel therapeutic approach, and we show here that administration to wild-type mice of (R)-1-[6-(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine -2- carboxylic acid, a drug that inhibits SAP binding, significantly prolonged survival during lethal infection with E. coli J5.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11121061      PMCID: PMC18962          DOI: 10.1073/pnas.97.26.14584

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation.

Authors:  C J de Haas; E M van Leeuwen; T van Bommel; J Verhoef; K P van Kessel; J A van Strijp
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Streptococcal pyrogenic exotoxin A release, distribution, and role in a murine model of fasciitis and multiorgan failure due to Streptococcus pyogenes.

Authors:  S Sriskandan; D Moyes; L K Buttery; T Krausz; T J Evans; J Polak; J Cohen
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

3.  Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum.

Authors:  M B Pepys; P J Butler
Journal:  Biochem Biophys Res Commun       Date:  1987-10-14       Impact factor: 3.575

4.  Amyloid P component binds to keratin bodies in human skin and to isolated keratin filament aggregates in vitro.

Authors:  H Hintner; J Booker; J Ashworth; J Auböck; M B Pepys; S M Breathnach
Journal:  J Invest Dermatol       Date:  1988-07       Impact factor: 8.551

5.  Human serum amyloid P component, a circulating lectin with specificity for the cyclic 4,6-pyruvate acetal of galactose. Interactions with various bacteria.

Authors:  C R Hind; P M Collins; M L Baltz; M B Pepys
Journal:  Biochem J       Date:  1985-01-01       Impact factor: 3.857

6.  Isolation of serum amyloid P-component (protein SAP) in the mouse.

Authors:  M B Pepys
Journal:  Immunology       Date:  1979-07       Impact factor: 7.397

7.  Binding specificity of serum amyloid P component for the pyruvate acetal of galactose.

Authors:  C R Hind; P M Collins; D Renn; R B Cook; D Caspi; M L Baltz; M B Pepys
Journal:  J Exp Med       Date:  1984-04-01       Impact factor: 14.307

8.  Serum amyloid P component binds to cell nuclei in vitro and to in vivo deposits of extracellular chromatin in systemic lupus erythematosus.

Authors:  S M Breathnach; H Kofler; N Sepp; J Ashworth; D Woodrow; M B Pepys; H Hintner
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

9.  Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein.

Authors:  F C de Beer; A K Soutar; M L Baltz; I M Trayner; A Feinstein; M B Pepys
Journal:  J Exp Med       Date:  1982-07-01       Impact factor: 14.307

10.  Fibronectin and C4-binding protein are selectively bound by aggregated amyloid P component.

Authors:  F C de Beer; M L Baltz; S Holford; A Feinstein; M B Pepys
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

View more
  50 in total

Review 1.  The immunopathogenesis of meningococcal disease.

Authors:  A J Kvalsvig; D J Unsworth
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

2.  Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide.

Authors:  Madathilparambil V Suresh; Sanjay K Singh; Donald A Ferguson; Alok Agrawal
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

3.  New features of invasive candidiasis in humans: amyloid formation by fungi and deposition of serum amyloid P component by the host.

Authors:  Kevin B Gilchrist; Melissa C Garcia; Richard Sobonya; Peter N Lipke; Stephen A Klotz
Journal:  J Infect Dis       Date:  2012-07-16       Impact factor: 5.226

4.  The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice.

Authors:  Jeremy S Brown; Tracy Hussell; Sarah M Gilliland; David W Holden; James C Paton; Michael R Ehrenstein; Mark J Walport; Marina Botto
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-11       Impact factor: 11.205

5.  Human serum proteins bind to Sporothrix schenckii conidia with differential effects on phagocytosis.

Authors:  Silvia Guzman Beltrán; Jazmín Sanchez Morales; Augusto González Canto; Alma Escalona Montaño; Haydee Torres Guerrero
Journal:  Braz J Microbiol       Date:  2020-05-07       Impact factor: 2.476

6.  Efflux transport of serum amyloid P component at the blood-brain barrier.

Authors:  Szilvia Veszelka; Judit Laszy; Tamás Pázmány; László Németh; Izabella Obál; László Fábián; Gábor Szabó; Csongor S Abrahám; Mária A Deli; Zoltán Urbányi
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2013-11-21

7.  Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?

Authors:  Julian D Gillmore; Winston L Hutchinson; Jeff Herbert; Alison Bybee; Daniel A Mitchell; Robert P Hasserjian; Ken-Ichi Yamamura; Misao Suzuki; Caroline A Sabin; Mark B Pepys
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

8.  Bordetella pertussis acquires resistance to complement-mediated killing in vivo.

Authors:  Elizabeth J Pishko; David J Betting; Christina S Hutter; Eric T Harvill
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  Investigating interactions of the pentraxins serum amyloid P component and C-reactive protein by mass spectrometry.

Authors:  J Andrew Aquilina; Carol V Robinson
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

10.  Aggregated IgG inhibits the differentiation of human fibrocytes.

Authors:  Darrell Pilling; Nancy M Tucker; Richard H Gomer
Journal:  J Leukoc Biol       Date:  2006-03-16       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.